Engineering HIV-resistant human CD4+ T cells with CXCR4-specific zinc-finger nucleases

PLoS Pathogens

Volumn 7, Issue 4, 2011, Pages

  Wilen, Craig B ^a   Wang, Jianbin ^b   Tilton, John C ^a,e   Miller, Jeffrey C ^b   Kim, Kenneth A ^b   Rebar, Edward J ^b   Sherrill Mix, Scott A ^a   Patro, Sean C ^a   Secreto, Anthony J ^a   Jordan, Andrea P O ^a   Lee, Gary ^b   Kahn, Joshua ^b   Aye, Pyone P ^c   Bunnell, Bruce A ^c   Lackner, Andrew A ^c   Hoxie, James A ^a   Danet Desnoyers, Gwenn A ^a   Bushman, Frederic D ^a   Riley, James L ^d   Gregory, Philip D ^b   June, Carl H ^d   Holmes, Michael C ^b   Doms, Robert W ^a   more..

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b SANGAMO BIOSCIENCES INC   (United States)

^c TULANE NATIONAL PRIMATE RESEARCH CENTER   (United States)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

^e CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE RECEPTOR CXCR4; NUCLEASE; ZINC FINGER PROTEIN; CHEMOKINE RECEPTOR CCR5; CXCR4 PROTEIN, HUMAN; DEOXYRIBONUCLEASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BIOENGINEERING; CCR5 STRAIN; CD4+ T LYMPHOCYTE; CELL DISRUPTION; CELL DIVISION; CELL PROLIFERATION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; MOUSE; NONHUMAN; VIRUS MUTANT; VIRUS STRAIN; ANIMAL; AUTOTRANSPLANTATION; BIOSYNTHESIS; DISEASE MODEL; GENETIC ENGINEERING; GENETICS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOLOGY; MACACA MULATTA; METABOLISM; TRANSPLANTATION; VIRUS ENTRY; XENOGRAFT;

HUMAN IMMUNODEFICIENCY VIRUS 1;

ANIMALS; CD4-POSITIVE T-LYMPHOCYTES; CELL PROLIFERATION; DEOXYRIBONUCLEASES; DISEASE MODELS, ANIMAL; GENETIC ENGINEERING; HIV INFECTIONS; HIV-1; HUMANS; MACACA MULATTA; MICE; RECEPTORS, CCR5; RECEPTORS, CXCR4; TRANSPLANTATION, AUTOLOGOUS; TRANSPLANTATION, HETEROLOGOUS; VIRUS INTERNALIZATION;

EID: 79955785236     PISSN: 15537366     EISSN: 15537374     Source Type: Journal    
DOI: 10.1371/journal.ppat.1002020     Document Type: Article

References (62)

1. Tilton JC, Doms RW, (2010) Entry inhibitors in the treatment of HIV-1 infection. Antiviral Res 85: 91-100.
2. Liu R, Paxton WA, Choe S, Ceradini D, Martin SR, et al. (1996) Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection. Cell 86: 367-77.
3. Samson M, Libert F, Doranz BJ, Rucker J, Liesnard C, et al. (1996) Resistance to HIV-1 infection in caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene. Nature 382: 722-5.
4. Dean M, Carrington M, Winkler C, Huttley GA, Smith MW, et al. (1996) Genetic restriction of HIV-1 infection and progression to AIDS by a deletion allele of the CKR5 structural gene. Hemophilia Growth and Development Study, Multicenter AIDS Cohort Study, Multicenter Hemophilia Cohort Study, San Francisco City Cohort, ALIVE Study. Science 273: 1856-62.
5. Huang Y, Paxton WA, Wolinsky SM, Neumann AU, Zhang L, et al. (1996) The role of a mutant CCR5 allele in HIV-1 transmission and disease progression. Nat Med 2: 1240-3.
6. Hutter G, Nowak D, Mossner M, Ganepola S, Mussig A, et al. (2009) Long-term control of HIV by CCR5 Delta32/Delta32 stem-cell transplantation. N Engl J Med 360: 692-8.
7. Scarlatti G, Tresoldi E, Bjorndal A, Fredriksson R, Colognesi C, et al. (1997) In vivo evolution of HIV-1 co-receptor usage and sensitivity to chemokine-mediated suppression. Nat Med 3: 1259-65.
8. Connor RI, Sheridan KE, Ceradini D, Choe S, Landau NR, (1997) Change in coreceptor use correlates with disease progression in HIV-1-infected individuals. J Exp Med 185: 621-8.
9. Westby M, Lewis M, Whitcomb J, Youle M, Pozniak AL, et al. (2006) Emergence of CXCR4-using human immunodeficiency virus type 1 (HIV-1) variants in a minority of HIV-1-infected patients following treatment with the CCR5 antagonist maraviroc is from a pretreatment CXCR4-using virus reservoir. J Virol 80: 4909-20.
10. Hendrix CW, Flexner C, MacFarland RT, Giandomenico C, Fuchs EJ, et al. (2000) Pharmacokinetics and safety of AMD-3100, a novel antagonist of the CXCR-4 chemokine receptor, in human volunteers. Antimicrob Agents Chemother 44: 1667-73.
11. Hendrix CW, Collier AC, Lederman MM, Schols D, Pollard RB, et al. (2004) Safety, pharmacokinetics, and antiviral activity of AMD3100, a selective CXCR4 receptor inhibitor, in HIV-1 infection. J Acquir Immune Defic Syndr 37: 1253-62.
12. Tilton JC, Wilen CB, Didigu CA, Sinha R, Harrison JE, et al. (2010) A maraviroc-resistant HIV-1 with narrow cross-resistance to other CCR5 antagonists depends on both N-terminal and extracellular loop domains of drug-bound CCR5. J Virol 84: 10863-76.
13. Tilton JC, Amrine-Madsen H, Miamidian JL, Kitrinos KM, Pfaff J, et al. (2010) HIV type 1 from a patient with baseline resistance to CCR5 antagonists uses drug-bound receptor for entry. AIDS Res Hum Retroviruses 26: 13-24.
14. Westby M, Smith-Burchnell C, Mori J, Lewis M, Mosley M, et al. (2007) Reduced maximal inhibition in phenotypic susceptibility assays indicates that viral strains resistant to the CCR5 antagonist maraviroc utilize inhibitor-bound receptor for entry. J Virol 81: 2359-71.
15. Ogert RA, Wojcik L, Buontempo C, Ba L, Buontempo P, et al. (2008) Mapping resistance to the CCR5 co-receptor antagonist vicriviroc using heterologous chimeric HIV-1 envelope genes reveals key determinants in the C2-V5 domain of gp120. Virology 373: 387-99.
16. Tsibris AM, Sagar M, Gulick RM, Su Z, Hughes M, et al. (2008) In vivo emergence of vicriviroc resistance in a human immunodeficiency virus type 1 subtype C-infected subject. J Virol 82: 8210-4.
17. Bai J, Gorantla S, Banda N, Cagnon L, Rossi J, et al. (2000) Characterization of anti-CCR5 ribozyme-transduced CD34+ hematopoietic progenitor cells in vitro and in a SCID-hu mouse model in vivo. Mol Ther 1: 244-54.
18. DiGiusto DL, Krishnan A, Li L, Li H, Li S, et al. (2010) RNA-based gene therapy for HIV with lentiviral vector-modified CD34(+) cells in patients undergoing transplantation for AIDS-related lymphoma. Sci Transl Med 2: 36ra43.
19. Swan CH, Buhler B, Steinberger P, Tschan MP, Barbas CF, (2006) T-cell protection and enrichment through lentiviral CCR5 intrabody gene delivery. Gene Ther 13: 1480-92.
20. Luis Abad J, Gonzalez MA, del Real G, Mira E, Manes S, et al. (2003) Novel interfering bifunctional molecules against the CCR5 coreceptor are efficient inhibitors of HIV-1 infection. Mol Ther 8: 475-84.
21. Anderson J, Banerjea A, Akkina R, (2003) Bispecific short hairpin siRNA constructs targeted to CD4, CXCR4, and CCR5 confer HIV-1 resistance. Oligonucleotides 13: 303-12.
22. Anderson J, Banerjea A, Planelles V, Akkina R, (2003) Potent suppression of HIV type 1 infection by a short hairpin anti-CXCR4 siRNA. AIDS Res Hum Retroviruses 19: 699-706.
23. Perez EE, Wang J, Miller JC, Jouvenot Y, Kim KA, et al. (2008) Establishment of HIV-1 resistance in CD4+ T cells by genome editing using zinc-finger nucleases. Nat Biotechnol 26: 808-16.
24. Mani M, Kandavelou K, Dy FJ, Durai S, Chandrasegaran S, et al. (2005) Design, engineering, and characterization of zinc finger nucleases. Biochem Biophys Res Commun 335: 447-57.
25. Miller JC, Holmes MC, Wang J, Guschin DY, Lee YL, et al. (2007) An improved zinc-finger nuclease architecture for highly specific genome editing. Nat Biotechnol 25: 778-85.
26. Podhajska AJ, Szybalski W, (1985) Conversion of the FokI endonuclease to a universal restriction enzyme: cleavage of phage M13mp7 DNA at predetermined sites. Gene 40: 175-82.
27. Durai S, Mani M, Kandavelou K, Wu J, Porteus MH, et al. (2005) Zinc finger nucleases: custom-designed molecular scissors for genome engineering of plant and mammalian cells. Nucleic Acids Res 33: 5978-90.
28. Holt N, Wang J, Kim K, Friedman G, Wang X, et al. (2010) Human hematopoietic stem/progenitor cells modified by zinc-finger nucleases targeted to CCR5 control HIV-1 in vivo. Nat Biotechnol 28: 839-47.
29. Urnov FD, Miller JC, Lee YL, Beausejour CM, Rock JM, et al. (2005) Highly efficient endogenous human gene correction using designed zinc-finger nucleases. Nature 435: 646-51.
30. Isalan M, Choo Y, (2001) Rapid, high-throughput engineering of sequence-specific zinc finger DNA-binding proteins. Methods Enzymol 340: 593-609.
31. Jamieson AC, Miller JC, Pabo CO, (2003) Drug discovery with engineered zinc-finger proteins. Nat Rev Drug Discov 2: 361-8.
32. Isalan M, Klug A, Choo Y, (2001) A rapid, generally applicable method to engineer zinc fingers illustrated by targeting the HIV-1 promoter. Nat Biotechnol 19: 656-60.
33. Nilsson M, Ljungberg J, Richter J, Kiefer T, Magnusson M, et al. (2004) Development of an adenoviral vector system with adenovirus serotype 35 tropism; efficient transient gene transfer into primary malignant hematopoietic cells. J Gene Med 6: 631-41.
34. Levine BL, Mosca JD, Riley JL, Carroll RG, Vahey MT, et al. (1996) Antiviral effect and ex vivo CD4+ T cell proliferation in HIV-positive patients as a result of CD28 costimulation. Science 272: 1939-43.
35. Onlamoon N, Hudson K, Bryan P, Mayne AE, Bonyhadi M, et al. (2006) Optimization of in vitro expansion of macaque CD4 T cells using anti-CD3 and co-stimulation for autotransfusion therapy. J Med Primatol 35: 178-93.
36. Onlamoon N, Plagman N, Rogers KA, Mayne AE, Bostik P, et al. (2007) Anti-CD3/28 mediated expansion of macaque CD4+ T cells is polyclonal and provides extended survival after adoptive transfer. J Med Primatol 36: 206-18.
37. Brelot A, Heveker N, Adema K, Hosie MJ, Willett B, et al. (1999) Effect of mutations in the second extracellular loop of CXCR4 on its utilization by human and feline immunodeficiency viruses. J Virol 73: 2576-86.
38. Lu Z, Berson JF, Chen Y, Turner JD, Zhang T, et al. (1997) Evolution of HIV-1 coreceptor usage through interactions with distinct CCR5 and CXCR4 domains. Proc Natl Acad Sci U S A 94: 6426-31.
39. Leon RP, Hedlund T, Meech SJ, Li S, Schaack J, et al. (1998) Adenoviral-mediated gene transfer in lymphocytes. Proc Natl Acad Sci USA 95: 13159-64.
40. Doyon Y, McCammon JM, Miller JC, Faraji F, Ngo C, et al. (2008) Heritable targeted gene disruption in zebrafish using designed zinc-finger nucleases. Nat Biotechnol 26: 702-8.
41. Lloyd A, Plaisier CL, Carroll D, Drews GN, (2005) Targeted mutagenesis using zinc-finger nucleases in Arabidopsis. Proc Natl Acad Sci USA 102: 2232-7.
42. Brelot A, Heveker N, Pleskoff O, Sol N, Alizon M, (1997) Role of the first and third extracellular domains of CXCR-4 in human immunodeficiency virus coreceptor activity. J Virol 71: 4744-51.
43. Roulet E, Busso S, Camargo AA, Simpson AJ, Mermod N, et al. (2002) High-throughput SELEX SAGE method for quantitative modeling of transcription-factor binding sites. Nat Biotechnol 20: 831-5.
44. Famulok M, Huttenhofer A, (1996) In vitro selection analysis of neomycin binding RNAs with a mutagenized pool of variants of the 16S rRNA decoding region. Biochemistry 35: 4265-70.
45. Morales J, Al-Sharif L, Khalil DS, Shinwari JM, Bavi P, et al. (2009) Homozygous mutations in ADAMTS10 and ADAMTS17 cause lenticular myopia, ectopia lentis, glaucoma, spherophakia, and short stature. Am J Hum Genet 85: 558-68.
46. Leung AC, Wong VC, Yang LC, Chan PL, Daigo Y, et al. (2008) Frequent decreased expression of candidate tumor suppressor gene, DEC1, and its anchorage-independent growth properties and impact on global gene expression in esophageal carcinoma. Int J Cancer 122: 587-94.
47. Carroll RG, Riley JL, Levine BL, Feng Y, Kaushal S, et al. (1997) Differential regulation of HIV-1 fusion cofactor expression by CD28 costimulation of CD4+ T cells. Science 276: 273-6.
48. Hartley O, Klasse PJ, Sattentau QJ, Moore JP, (2005) V3: HIV's switch-hitter. AIDS Res Hum Retroviruses 21: 171-89.
49. Wilk T, Pfeiffer T, Bosch V, (1992) Retained in vitro infectivity and cytopathogenicity of HIV-1 despite truncation of the C-terminal tail of the env gene product. Virology 189: 167-77.
50. Harrison JE, Lynch JB, Sierra LJ, Blackburn LA, Ray N, et al. (2008) Baseline resistance of primary human immunodeficiency virus type 1 strains to the CXCR4 inhibitor AMD3100. J Virol 82: 11695-704.
51. Nagasawa T, Hirota S, Tachibana K, Takakura N, Nishikawa S, et al. (1996) Defects of B-cell lymphopoiesis and bone-marrow myelopoiesis in mice lacking the CXC chemokine PBSF/SDF-1. Nature 382: 635-8.
52. Bleul CC, Fuhlbrigge RC, Casasnovas JM, Aiuti A, Springer TA, (1996) A highly efficacious lymphocyte chemoattractant, stromal cell-derived factor 1 (SDF-1). J Exp Med 184: 1101-9.
53. Brave M, Farrell A, Ching Lin S, Ocheltree T, Pope Miksinski S, et al. (2010) FDA review summary: Mozobil in combination with granulocyte colony-stimulating factor to mobilize hematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation. Oncology 78: 282-8.
54. Newrzela S, Cornils K, Li Z, Baum C, Brugman MH, et al. (2008) Resistance of mature T cells to oncogene transformation. Blood 112: 2278-86.
55. June CH, Blazar BR, Riley JL, (2009) Engineering lymphocyte subsets: tools, trials and tribulations. Nat Rev Immunol 9: 704-16.
56. Hacein-Bey-Abina S, Hauer J, Lim A, Picard C, Wang GP, et al. (2010) Efficacy of gene therapy for X-linked severe combined immunodeficiency. N Engl J Med 363: 355-64.
57. Cavazzana-Calvo M, Payen E, Negre O, Wang G, Hehir K, et al. (2010) Transfusion independence and HMGA2 activation after gene therapy of human beta-thalassaemia. Nature 467: 318-22.
58. Boboila C, Yan C, Wesemann DR, Jankovic M, Wang JH, et al. (2010) Alternative end-joining catalyzes class switch recombination in the absence of both Ku70 and DNA ligase 4. J Exp Med 207: 417-27.
59. Wilkin TJ, Su Z, Kuritzkes DR, Hughes M, Flexner C, et al. (2007) HIV type 1 chemokine coreceptor use among antiretroviral-experienced patients screened for a clinical trial of a CCR5 inhibitor: AIDS Clinical Trial Group A5211. Clin Infect Dis 44: 591-5.
60. Hoxie JA, LaBranche CC, Endres MJ, Turner JD, Berson JF, et al. (1998) CD4-independent utilization of the CXCR4 chemokine receptor by HIV-1 and HIV-2. J Reprod Immunol 41: 197-211.
61. Este JA, Cabrera C, Blanco J, Gutierrez A, Bridger G, et al. (1999) Shift of clinical human immunodeficiency virus type 1 isolates from X4 to R5 and prevention of emergence of the syncytium-inducing phenotype by blockade of CXCR4. J Virol 73: 5577-85.
62. Philpott S, Weiser B, Anastos K, Kitchen CM, Robison E, et al. (2001) Preferential suppression of CXCR4-specific strains of HIV-1 by antiviral therapy. J Clin Invest 107: 431-8.